[Oseltamivir in pregnancy, lactation and neonatal period--comparison of international recommendations].

BACKGROUND: In the current influenza A (H1N1) pandemia, data on neonatal and maternal Oseltamivir chemoprophylaxis and treatment are limited. Recommendations of national and international health authorities do not compensate for a lack of controlled studies on pharmacokinetics and safety. However, the level of consent may contribute to individual clinical decisions. METHODS: We have reviewed online recommendations by health authorities in the context of the current literature. RESULTS: Given the limited database, there is a high level of consent among recommendations issued by health authorities regarding treatment with Oseltamivir and breast-feeding. DISCUSSION: The majority of recommendations do not regard treatment with Oseltamivir as a contraindication to breast-feeding. Antiviral chemoprophylaxis of influenza A (H1N1) infection in preterm infants is not recommended due to the lack of data on its pharmacokinetics and safety. CONCLUSION: Variable recommendations have been issued regarding the choice of neuraminidase inhibitors in pregnancy. Additional information on the pharmacokinetics and safety of neuraminidase inhibitors for breast-feeding mothers and neonates is essential in order to address potential future pandemics.